Andere talen Fate Therapeutics, Inc.

Aandelen

FATE

US31189P1021

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 02-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
4,1 ^USD	+0,24%		-4,65%	+9,63%

22/04	Fate Therapeutics, Inc. kondigt de presentatie aan van FT819 Proof-of-Concept-gegevens voor B cel-gemedieerde auto-immuunziekten op de jaarlijkse ASGCT-bijeenkomst	CI
19/03	Fate Therapeutics prijst $100 miljoen aanbieding, onderhandse plaatsing	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting	22/04
Fate Therapeutics, Inc. Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting	22/04
Fate Therapeutics Reports New Employee Inducement Award under Nasdaq Listing Rule 5635(4)	03/04
Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference	03/04
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)	02/04
Fate Therapeutics, Inc. announced that it has received $19.996366 million in funding from Redmile Group, LLC	21/03
Fate Therapeutics Prices $100 Million Offering, Private Placement	19/03
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement	19/03
Fate Therapeutics, Inc. announced that it expects to receive $19.996366 million in funding from Redmile Group, LLC	19/03
Fate Therapeutics, Inc.(NasdaqGM:FATE) added to S&P Biotechnology Select Industry Index	18/03
Fate Therapeutics Reports New Employee Inducement Award under Nasdaq Listing Rule 5635(4)	06/03
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)	05/03
Fate Therapeutics to Present at Upcoming March Investor Conferences	04/03
Fate Therapeutics to Present at Upcoming March Investor Conferences	01/03
Fate Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/02
Fate Therapeutics: Q4 Earnings Snapshot	26/02
Earnings Flash (FATE) FATE THERAPEUTICS Posts Q4 Revenue $1.7M, vs. Street Est of $1.5M	26/02
Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates	26/02
Fate Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	26/02
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results	15/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Fate Therapeutics, Inc.

Aandelen

FATE

US31189P1021

Andere talen

Filters